Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J. Hsieh, Robert J. Motzer, Almedina Redzematovic et al.|European Urology|2016Cited by 204
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibitionCarolina Nunes, Frank Speleman, Lisa Depestel et al.|Science Advances|2022Cited by 49